查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495997

全球酵素结合免疫吸附检测法(ELISA) 市场 - 2024 年至 2029 年预测

Global Enzyme-Linked Immunosorbent Assay (ELISA) Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

酵素结合免疫吸附检测法(ELISA) 市场预计将以 5.56% 的复合年增长率成长，从 2022 年的 21.38 亿美元增至 2029 年的 31.23 亿美元。

ELISA（酵素结合免疫吸附检测法）或酵素免疫分析法测定（EIA）是一种基于板的测量技术，旨在检测和定量胜胜肽、蛋白质、抗体和荷尔蒙等物质。 ELISA 通常用作更详细测试之前的筛检工具。由于 ELISA 反应物固定在微孔盘表面，因此在测定过程中可以轻鬆分离结合和未结合的物质。这使其成为测定粗製剂中特定分析物的强大工具。

ELISA 的常见诊断用途包括 HIV 感染、怀孕检测和蛋白质检测。预计 ELISA 市场在预测期内将稳定成长。这种增长可能是由于感染疾病和慢性病患病率的上升以及对 ELISA 作为具有成本效益的诊断工具的需求。然而，有关 ELISA 的严格监管要求和不利的报销政策可能会阻碍预测期内的市场成长。

市场驱动因素：

  • 感染疾病日益流行预计将推动市场成长。

推动市场扩张的关键因素之一是爱滋病毒、肝炎、疟疾、登革热和流感等感染疾病率的上升。世界卫生组织估计，到 2021年终，全球有 3,840 万名爱滋病毒感染者，其中三分之二以上居住在非洲。世界卫生组织也声称，登革热是世界面临的十大健康威胁之一。过去 50 年来，全球登革热发生率增加了约 3,000%。世界卫生组织也估计，2019 年全球有超过 2.96 亿人感染B型肝炎。

由于感染疾病发生率不断增加，对诊断的需求预计也会增加。由于越来越多地使用尖端诊断技术（例如酵素结合免疫吸附测试）来筛检这些疾病，预计该市场将会扩大。

此外，全球越来越多的老年人患有感染疾病和慢性病的高风险并需要常规诊断，预计将刺激市场扩张。根据 NCBI（美国生物技术资讯中心）于 2021 年发布的消息，与年轻人相比，老年患者更有可能发生潜在危险的疾病。因此，这些因素预计将增加对酵素结合免疫吸附检测法的需求，从而显着提高市场成长。

  • 疾病诊断领域预计将大幅推动市场成长。

越来越多地使用酵素结合免疫吸附测定测试来诊断特定抗原，预计将占据疾病诊断市场的重要份额。世界卫生组织估计，到 2022 年，非传染性疾病每年将导致约 4,100 万人死亡，占全球死亡人数的 71%。此类疾病的发生增加了对有效诊断技术（例如用于快速检测的 ELISA）的需求，以最大限度地降低死亡率。

此外，根据全球癌症观察站的数据，2020年将有约1,930万人新诊断出癌症，约1,000万人将死于癌症。由于 ELISA 是评估抗原的有用工具，全球癌症发生率的上升正在推动其需求。

根据 Nature Scientific 2020 年的一项研究，酵素结合免疫吸附检测法可用于寻找乳腺癌和前列腺癌抗原。这种准确的抗原筛检和具有成本效益的诊断预计将在分析期间增加 ELISA 需求并推动市场扩张。

预计北美将占据很大的市场份额

由于ELISA等筛检设备技术突破的市场开拓迅速，美国很可能主导全球市场。该地区多种感染疾病和慢性疾病的发生率不断增加，增加了对酵素酵素结合免疫吸附检测法的需求。例如，美国疾病管制与预防中心 (CDC) 报告称，到 2022 年，超过 60% 的美国人将患有至少一种慢性疾病，例如癌症、心血管疾病或中风。

由于研发支出的增加和诊断资金的大量投入，预计该地区的市场将会成长。根据 Binder Dijker Otte USA 2020 年报告，生技指数中的上市公司 2020 年研发支出平均成长约 16% 至 2.8425 亿美元。

此外，2021 年，美国卫生与公众服务部宣布从美国救援计画中拨款 6.5 亿美元，用于提高快速、高品质诊断测试的生产能力。因此，所有这些方面预计将在预测期内很好地支持北美区域市场。

主要发展

  • 2022 年 9 月 - Neogen Corporation 推出了用于腰果检测的 Veratox VIP 测定法，作为其增强型定量 ELISA 系列的第二部分。无论样品类型如何，这种创新测试都能提供稳健的性能，并保持 Veratox 产品线的简单测试方法。 Neogen 旨在透过提供高度灵敏的测试来保护世界各地的消费者，这些测试甚至可以检测出最低水平的食品过敏原。此测试对低至 0.2 ppm 的腰果蛋白水平具有很高的特异性。 Veratox VIP for Cashew 使用与现有 Veratox 产品线相同的测试方法，可在 30 分钟内提供结果，并且还包括即用型无害试剂。
  • 2022 年 9 月 - J Mitra 推出 HCV Gen 4 Ag &Ab Microlisa，这是第四代基于 ELISA 的 HCV 测试。这种体外定性 ELISA 可检测人类血清或血浆中的 HCV 核心抗原和 HCV 抗体。此检测旨在帮助早期发现慢性HCV感染，与第三代检测相比，将急性感染的窗口期缩短5至7週。此测试对于高风险族群和同时感染 HIV/HCV 的患者特别有用。 ELISA 测试具有高灵敏度和特异性，批次处理可实现快速週转时间。 J Mitra 在改善印度丙肝诊断方面发挥关键作用。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章酵素结合免疫吸附检测法(ELISA) 全球市场：依类型

  • 介绍
  • 间接ELISA
  • 夹心ELISA
  • 竞争性ELISA

第六章酵素结合免疫吸附检测法（ELISA）全球市场：依应用

  • 介绍
  • 饮食
  • 疫苗开发
  • 免疫学
  • 诊断
  • 药物监测
  • 其他的

第七章酵素结合免疫吸附检测法(ELISA) 全球市场：依最终使用者分类

  • 介绍
  • 製药业
  • 医院和诊所
  • 诊断中心
  • 其他的

第八章酵素结合免疫吸附检测法（ELISA）全球市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Pestka Biomedical Laboratories, Inc.
  • Diaclone SAS
  • Thermo Fisher Scientific Inc.
  • Azure Biosystems Inc.
  • R&D Systems, Inc
  • RayBiotech, Inc.
  • Elabscience
  • BioLegend, Inc.
  • Randox Toxicology
  • STEMCELL Technologies Inc.
  • Genway Biotech, Inc.
简介目录
Product Code: KSI061611695

The global Enzyme-Linked Immunosorbent Assay (ELISA) market is projected to grow at a CAGR of 5.56% increasing from US$2.138 billion in 2022 to US$3.123 billion in 2029.

ELISA (enzyme-linked immunosorbent assay) or enzyme immunoassay (EIA) is a plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA is often used as a screening tool before further in-depth tests are ordered. Reactants of the ELISA are immobilized to the microplate surface, making it easy to separate bound from non-bound material during the assay. This makes it a powerful tool for measuring specific analytes within a crude preparation.

The common diagnostic applications of ELISA are HIV infection, pregnancy tests, detection of proteins, etc. The ELISA market is expected to show robust growth during the forecast period. The growth may be attributed to the rising incidence of infectious and chronic diseases, which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements, as well as unfavorable reimbursement policies about ELISA, might hamper the market growth during the given time frame.

Market Drivers:

  • The rising prevalence of infectious diseases is predicted to propel the market growth.

One of the key drivers fuelling the market's expansion is the rising prevalence of infectious diseases like HIV, Hepatitis, malaria, dengue, and influenza, among other ailments. At the end of 2021, the WHO estimated that there were 38.4 million HIV-positive individuals worldwide, with more than two-thirds of them living in Africa. The WHO also claimed that dengue fever was among the top ten health threats facing the world. Over the past 50 years, dengue incidences have increased by about 3000% worldwide. WHO also estimated that more than 296 million individuals worldwide have hepatitis B infection as of 2019.

The demand for diagnosis is anticipated to rise as a result of the rising occurrence of infectious diseases. The market is anticipated to expand due to the rising use of cutting-edge diagnostic techniques for screening these disorders, such as enzyme-linked immunosorbent tests.

Additionally, the growing geriatric population, which is globally at risk of contracting illnesses and chronic diseases and requires routine diagnosis, is anticipated to fuel market expansion. In comparison to younger individuals, potentially dangerous illnesses are more likely in elderly patients, according to the NCBI (National Center for Biotechnology Information), which published this information in 2021. Thus, it is anticipated that these factors will considerably raise the market's growth by boosting demand for enzyme-linked immunosorbent assays.

  • The disease diagnosis segment is anticipated to surge the market growth.

Due to the growing use of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a sizable share of the disease diagnosis market has been predicted. In 2022, the WHO estimated that non-communicable illnesses caused around 41 million deaths each year, equivalent to 71% of all deaths worldwide. Due to these occurrences, there is now a greater need for efficient diagnostic techniques like ELISA for prompt detection to minimize death occurrences.

Additionally, according to the Global Cancer Observatory, there were approximately 19.3 million new cases of cancer and nearly 10.0 million cancer deaths worldwide in 2020. As ELISA is a useful instrument for assessing antigens, the rise in cancer incidence around the world is driving up demand for it.

The Enzyme-Linked Immunosorbent Assay can be used to find both breast cancer antigens and prostate cancer antigens, according to a 2020 Nature Scientific study. Such accurate antigen screening and cost-effective diagnosis are anticipated to boost ELISA demand and drive the market's expansion during the analyzed period.

North America is Expected to Hold a Significant Share in the Market

Because of the rapid development of technological breakthroughs in screening instruments like ELISA, the US is likely to dominate the global market. The increasing incidences of multiple infectious and chronic diseases in this demography are contributing to the strong demand for Enzyme-Linked Immunosorbent Assay. For instance, the CDC (Centre for Ailment Control and Prevention) reported in 2022 that over 60% of Americans had at least one chronic disease, such as cancer, cardiovascular disease, or stroke.

The market in this region is anticipated to grow as a result of rising R&D expenditures as well as numerous funding initiatives for diagnostics. Listed firms on the biotechnology index expanded their R&D spending by about 16% on average in 2020 to USD 284.25 million in the US, based on the Binder Dijker Otte USA Reports from 2020.

Additionally, in 2021, the Department of Health and Human Services said that it would deploy USD 650 million from the American rescue plan to increase production capabilities for swift, high-quality diagnostic tests. Therefore, it is projected that all of these aspects will support the North American regional market well over the predicted period.

Key Developments:

  • September 2022- Neogen Corporation introduced its Veratox VIP assay for cashew detection, the second in its enhanced quantitative ELISA line. This innovative test offers robust performance across sample types and maintains the simple testing methodology of the Veratox product line. Neogen aims to offer highly sensitive tests that can detect even the lowest levels of food allergens, protecting consumers worldwide. The test demonstrates a high level of specificity to very low levels of cashew protein, down to 0.2 ppm. The Veratox VIP for Cashew uses the same testing methodology as its existing Veratox product line, including a 30-minute time-to-result and ready-to-use, non-hazardous reagents.
  • September 2022- J Mitra introduced the HCV Gen 4 Ag & Ab Microlisa, a 4th Generation Elisa-based HCV test. This in-vitro qualitative ELISA detects HCV core antigens and antibodies against HCV in human serum or plasma. The test is designed to help detect chronic HCV infections early, reducing the window period for acute infection by 5-7 weeks compared to the 3rd generation test. The test is particularly useful in high-risk groups and HIV/HCV co-infected patients. The Elisa test offers higher sensitivity and specificity, and batch processing can result in a quick turnaround time. J Mitra has played a significant role in improving HCV diagnosis in India.

Segmentation:

By Type

  • Indirect ELISA
  • Sandwich ELISA
  • Competitive ELISA

By Application

  • Food and Beverage
  • Vaccine Development
  • Immunology
  • Diagnosis
  • Drug Monitoring
  • Others

By End Users

  • Pharmaceutical Industries
  • Hospitals and Clinics
  • Diagnostic Centres
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Indirect ELISA
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Sandwich ELISA
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Competitive ELISA
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Food and Beverage
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Vaccine Development
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Immunology
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Diagnosis
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Drug Monitoring
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness
  • 6.7. Others
    • 6.7.1. Market Opportunities and Trends
    • 6.7.2. Growth Prospects
    • 6.7.3. Geographic Lucrativeness

7. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Pharmaceutical Industries
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Hospitals and Clinics
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Diagnostic Centres
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. UK
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Australia
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. South Korea
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Thailand
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Taiwan
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects
      • 8.6.4.9. Others
        • 8.6.4.9.1. Market Opportunities and Trends
        • 8.6.4.9.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Pestka Biomedical Laboratories, Inc.
  • 10.2. Diaclone SAS
  • 10.3. Thermo Fisher Scientific Inc.
  • 10.4. Azure Biosystems Inc.
  • 10.5. R&D Systems, Inc
  • 10.6. RayBiotech, Inc.
  • 10.7. Elabscience
  • 10.8. BioLegend, Inc.
  • 10.9. Randox Toxicology
  • 10.10. STEMCELL Technologies Inc.
  • 10.11. Genway Biotech, Inc.